Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • Subject Terms:
      Infliximab*/administration & dosage ; Infliximab*/therapeutic use ; Infliximab*/pharmacokinetics ; Inflammatory Bowel Diseases*/drug therapy ; Inflammatory Bowel Diseases*/metabolism ; C-Reactive Protein*/metabolism ; C-Reactive Protein*/analysis ; Leukocyte L1 Antigen Complex*/analysis ; Administration, Intravenous*; Gastrointestinal Agents/administration & dosage ; Gastrointestinal Agents/therapeutic use ; Feces/chemistry ; Humans ; Female ; Male ; Adult ; Retrospective Studies ; Injections, Subcutaneous ; Middle Aged ; Treatment Outcome ; Drug Substitution
    • Abstract:
      Infliximab (IFX) has transformed the management of inflammatory bowel diseases (IBD). While intravenous (IV) IFX has been effective, a subcutaneous (SC) formulation offers advantages in convenience and cost. However, there is lack of evidence regarding the transition from IV to SC-IFX, especially for patients with inadequate responses. This study investigates the effectiveness of switching from IV to SC-IFX in patients with inadequate responses during IV maintenance therapy. A retrospective study enrolled IBD patients who transitioned to SC-IFX after demonstrating inadequate responses during IV maintenance therapy. The study collected data of demographics of patients and dose and therapies administered prior to the IV-IFX. Primary outcomes included improvements in C-reactive protein (CRP) or fecal calprotectin (FC) levels. This study evaluated the trough levels and its differences between pre- and post-switching. Among 44 patients included, 10 exhibited CRP elevation before the switch, with 6 showing normalization post-switch. Similarly, 42 patients had elevated FC levels pre-switch, with 26 experiencing reductions post-switch. Trough levels increased after the switch. However, there were no significant differences between responders and non-responders. This study is the first study to investigate the transition therapy of IV to SC-IFX in patients with inadequate response. This suggests that SC-IFX could be a viable alternative in the management of IBD. However, further research is necessary to evaluate its efficacy in a larger population of patients who exhibit inadequate responses during IV-IFX maintenance therapy.
      (© 2024. The Author(s).)
    • References:
      Clin Gastroenterol Hepatol. 2023 Aug;21(9):2338-2346.e3. (PMID: 35987302)
      Medicine (Baltimore). 2022 Sep 23;101(38):e30683. (PMID: 36197194)
      J Crohns Colitis. 2019 Oct 28;13(11):1410-1417. (PMID: 30989166)
      Gut. 2009 Apr;58(4):492-500. (PMID: 18832518)
      Lancet. 2002 May 4;359(9317):1541-9. (PMID: 12047962)
      N Engl J Med. 1997 Oct 9;337(15):1029-35. (PMID: 9321530)
      Inflamm Bowel Dis. 2024 Apr 3;30(4):517-528. (PMID: 37260346)
      Gastroenterology. 2006 Apr;130(4):1054-61. (PMID: 16618399)
      N Engl J Med. 2004 Feb 26;350(9):876-85. (PMID: 14985485)
      J Clin Gastroenterol. 2015 Aug;49(7):582-8. (PMID: 25844841)
      N Engl J Med. 2010 Apr 15;362(15):1383-95. (PMID: 20393175)
      N Engl J Med. 1999 May 6;340(18):1398-405. (PMID: 10228190)
      Biomedicines. 2022 Aug 30;10(9):. (PMID: 36140230)
      Lancet. 2012 Dec 1;380(9857):1909-15. (PMID: 23063316)
      BMC Health Serv Res. 2022 Nov 4;22(1):1319. (PMID: 36333704)
      Korean J Intern Med. 2022 Sep;37(5):885-894. (PMID: 35902371)
      J Crohns Colitis. 2022 Aug 4;16(7):1059-1069. (PMID: 35078228)
      N Engl J Med. 2005 Dec 8;353(23):2462-76. (PMID: 16339095)
      Gut. 2018 Feb;67(2):237-243. (PMID: 28053054)
      Gastroenterology. 2021 Apr;160(5):1570-1583. (PMID: 33359090)
      Gut. 2020 Aug;69(8):1432-1440. (PMID: 31822581)
      Gut. 2009 Apr;58(4):501-8. (PMID: 18832524)
      Adv Ther. 2022 Jun;39(6):2342-2364. (PMID: 34988877)
      Crohns Colitis 360. 2023 Jul 25;5(4):otad040. (PMID: 38028954)
      Clin Drug Investig. 2022 Jun;42(6):477-489. (PMID: 35657560)
      Gastroenterology. 2021 Jun;160(7):2340-2353. (PMID: 33676969)
      MAbs. 2021 Jan-Dec;13(1):1868078. (PMID: 33557682)
    • Grant Information:
      RS-2023-00248080 National Research Foundation of Korea
    • Contributed Indexing:
      Keywords: Inadequate response; Inflammatory bowel disease; Infliximab; Subcutaneous administration; Transition therapy
    • Accession Number:
      B72HH48FLU (Infliximab)
      9007-41-4 (C-Reactive Protein)
      0 (Leukocyte L1 Antigen Complex)
      0 (Gastrointestinal Agents)
    • Publication Date:
      Date Created: 20241017 Date Completed: 20241017 Latest Revision: 20241022
    • Publication Date:
      20260130
    • Accession Number:
      PMC11487171
    • Accession Number:
      10.1038/s41598-024-75693-7
    • Accession Number:
      39420116